Cyfra 21-1 - A prognostic factor for patients with carcinoma of head and neck unrelated to the stage of the disease

Prognostic Factors in Head and Neck Cancer

Sample size: 67 publication Evidence: moderate

Author Information

Author(s): I. Doweck, M. Barak, N. Uri, E. Greenberg

Primary Institution: Carmel Medical Center, Haifa, Israel

Hypothesis

What is the prognostic value of Cyfra 21-1 for patients with carcinoma of the head and neck?

Conclusion

Cyfra 21-1 is a prognostic factor for patients with carcinoma of the head and neck, unrelated to the stage of the disease.

Supporting Evidence

  • 32 patients had low levels of Cyfra 21-1 at diagnosis, with a 63% survival rate for 40 months.
  • 35 patients had Cyfra 21-1 levels above 1.5 ng/ml, with a 20% survival rate.

Takeaway

Doctors can use a blood test called Cyfra 21-1 to help predict how well patients with head and neck cancer will do, no matter how advanced their cancer is.

Methodology

The study evaluated Cyfra 21-1 levels in 67 patients with primary detection of carcinoma of the head and neck and followed their survival rates.

Participant Demographics

67 patients with primary detection of carcinoma of head and neck.

Statistical Information

P-Value

0.03

Statistical Significance

p<0.03

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication